Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4585

Sort by

Sort Order Select

Journal Articles

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

Naranie Shanmuganathan, Ilaria S. Pagani, David M. Ross, Sahee Park, Agnes S. M. Yong, Jodi A. Braley, Haley K. Altamura, Devendra K. Hiwase, David T. Yeung, Dong-Wook Kim, Susan Branford, Timothy P. Hughes

Blood (2021) 137 (9): 1196–1207.

https://doi.org/10.1182/blood.2020005514

Published: 2021

Includes: Supplemental data

Journal Articles

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

Blood (2020) 136 (5): 596–609.

https://doi.org/10.1182/blood.2019003636

Published: 2020

Includes: Supplemental data

Journal Articles

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Blood (2020) 135 (26): 2337–2353.

https://doi.org/10.1182/blood.2020004834

Published: 2020

Includes: Supplemental data

Journal Articles

Comprehensive Molecular Profiling of Idiopathic Erythrocytosis By Genetic Ancestry

Caitlin O'Neill, MD, Zarko Manojlovic, PhD BS, Ah-Reum Jeong, MD, Yili Xu, MS, Yuxin Jin, MS, Sharon Chang, BS, Eric Kwok, BS, Michelle Webb, MS, Casey O'Connell, MD

Blood (2019) 134 (Supplement_1): 945.

https://doi.org/10.1182/blood-2019-122619

Published: 2019

Journal Articles

Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)

Pascal Vannuffel, PhD, Luana Bavaro, Dr, Friedel Nollet, PhD, Asena Aynaci, Margherita Martelli, Dr, Helena Devos, Céline De Rop, Simona Soverini, PhD

Blood (2019) 134 (Supplement_1): 4660.

https://doi.org/10.1182/blood-2019-123409

Published: 2019

Journal Articles

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Blood (2019) 134 (Supplement_1): 1649.

https://doi.org/10.1182/blood-2019-127029

Published: 2019

Journal Articles

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Fernanda S Seguro, MD, Felipe VR Maciel, MD, Guilherme O Lopes, Luciana Nardinelli, M.Sc, Vanderson Rocha, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1651.

https://doi.org/10.1182/blood-2019-125989

Published: 2019

Journal Articles

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Alessandra Iurlo, MD PhD, Mario Annunziata, MD, Francesco Albano, MD, Luigia Luciano, MD, Raffaele Spadano, MD, Anna Rita Scortechini, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD, Monia Lunghi, MD PhD, Alessandra Malato, MD PhD, Nicola Di Renzo, MD, Alfonso Piciocchi, Angela Pellegrino, MSc, Claudia Galimberti, Robin Foà, MD, Massimo Breccia, MD

Blood (2019) 134 (Supplement_1): 1652.

https://doi.org/10.1182/blood-2019-126098

Published: 2019

Journal Articles

ABL Kinase Domain Mutation in Chronic Myeloid Leukemia - Compliance to Imatinib Matters

Jayachandran PK, MD MRCP, DM, Trivadi S Ganesan, MD FRCP, PhD, Nikita Mehra, MD DM, Krishnarathinam Kannan, MD DM, Manikandan Dhanushkodi, MD DM, Venkatraman Radhakrishnan, MD DM, Arun Kumar Rajan, MD DM, Joshi Archit Girishchandra, MD DM, Gangothri Selvarajan, MD DM, Parathan Karunakaran, MD DM, Tenali Gnana Sagar, MD DM

Blood (2019) 134 (Supplement_1): 1654.

https://doi.org/10.1182/blood-2019-125998

Published: 2019

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

The Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding and Represents a Druggable Target

Christophe Desterke, PhD, Sarah Pagliaro, Pharm D, Patricia Hugues, Annelise Bennaceur-Griscelli, MD PhD, Ali G Turhan, MD PhD

Blood (2019) 134 (Supplement_1): 1632.

https://doi.org/10.1182/blood-2019-124796

Published: 2019

Journal Articles

Shikonin Overcomes Drug Resistance and Induces Necroptosis By Regulating the Mir-92a-1-5p/Mlkl Axis in Chronic Myeloid Leukemia Cells

Xianbo Huang, MD PhD, Jie Jin, MD PhD, Wenbin Qian, MD PhD, Xiujin Ye, MD PhD

Blood (2019) 134 (Supplement_1): 1633.

https://doi.org/10.1182/blood-2019-125600

Published: 2019

Journal Articles

Splenic CD24 low Red Pulp Macrophages Provide an Alternate Niche for Chronic Myeloid Leukemia Stem Cells

Michael A Amrein, MD PhD, Elias D Bührer, MD PhD, Stefan Forster, MD, Stephan Isringhausen, Christian M Schürch, MD PhD, Salil S. Bhate, MMath, Mohamad Al Sayed, PhD, Cesar Nombela Arrieta, PhD, Ramin Radpour, PhD, Carsten Riether, PhD, Adrian F Ochsenbein, MD

Blood (2019) 134 (Supplement_1): 1634.

https://doi.org/10.1182/blood-2019-126593

Published: 2019

Journal Articles

The Interaction of Tumor Cells and Myeloid-Derived Suppressor Cells in Chronic Myelogenous Leukemia

Hui Xu, Zunmin Zhu, Xiaojian Zhu, Na Shen, Shu Zhou, Yicheng Zhang

Blood (2019) 134 (Supplement_1): 1636.

https://doi.org/10.1182/blood-2019-125563

Published: 2019

Journal Articles

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Ana Beatriz Pascoal Lopes, Eliana C Miranda, PhD, Valquíria Mariane Oliveira Póvoa, Bruna Rocha Vergílio, Graziele Cristina Pavan Furlin, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 1637.

https://doi.org/10.1182/blood-2019-128265

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Laurence Legros, MD PhD, Franck E Nicolini, MDPhD, Gabriel Etienne, MD PhD, Philippe Rousselot, MDPhD, Delphine Rea, MD, Stephane Giraudier, MD PhD, Agnès Guerci, MD PhD, Francoise Huguet, MD, Martine Gardembas, MD, Jean-Christophe Ianotto, MD PhD, Martine Escoffre-Barbe, MD, Valerie Coiteux, MD, Bruno Varet, MD, Stephane Morisset, BioStat, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 28.

https://doi.org/10.1182/blood-2019-123719

Published: 2019

Journal Articles

Difference in the Donor Selection Priority in Allogeneic Hematopoietic Stem Cell Transplantation According to Patient Age

Koji Kawamura, Junya Kanda, MD, Sachiko Seo, MDPhD, Fumihiko Kimura, MD PhD, Masahiro Hirayama, MD PhD, Naoyuki Uchida, MD PhD, Noriko Doki, MD PhD, Takahiro Fukuda, Yukiyasu Ozawa, MD PhD, Yuta Katayama, MD PhD, Minoko Takanashi, MD PhD, Yoshiko Atsuta, MD PhD, Yoshinobu Kanda, MD PhD

Blood (2019) 134 (Supplement_1): 46.

https://doi.org/10.1182/blood-2019-125032

Published: 2019

Journal Articles

Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR

Elisa Diral, MD, Philipp Le Coutre, MD, Enrico Marco Gottardi, Chiara Elena, MD, Micaela Bergamaschi, MD, Sarit Assouline, MD, Eros Di Bona, MD, Jessica Petiti, PhD, Fabio Stagno, MD, Alessandra Iurlo, MD PhD, Dong-Wook Kim, Alessandra Pirola, MSc, Maria Luisa Bonanomi, Patrizia Crivori, PhD, Rocco Piazza, MD PhD, Carmen Fava, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 29.

https://doi.org/10.1182/blood-2019-125226

Published: 2019

NARROW

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Comprehensive Molecular Profiling of Idiopathic Erythrocytosis By Genetic Ancestry

Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

ABL Kinase Domain Mutation in Chronic Myeloid Leukemia - Compliance to Imatinib Matters

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

The Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding and Represents a Druggable Target

Shikonin Overcomes Drug Resistance and Induces Necroptosis By Regulating the Mir-92a-1-5p/Mlkl Axis in Chronic Myeloid Leukemia Cells

Splenic CD24 low Red Pulp Macrophages Provide an Alternate Niche for Chronic Myeloid Leukemia Stem Cells

The Interaction of Tumor Cells and Myeloid-Derived Suppressor Cells in Chronic Myelogenous Leukemia

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Difference in the Donor Selection Priority in Allogeneic Hematopoietic Stem Cell Transplantation According to Patient Age

Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only